ChimeriVax-JE: Preliminary Phase III data

Acambis plc (LSE:ACM; ACAM), Cambridge, U.K.
Product: ChimeriVax-JE
Business: Infectious
Molecular target: Not applicable

Read the full 143 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE